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(14.1e6/kg vs. 15.85e6/kg, p value 0.0974). There was no
signiﬁcant difference in days to SC collection or number of
days of neutropenia.
Conclusion: Our retrospective analysis showed that
duration of neutropenia does increase signiﬁcantly with
increase in C dose, yet with an overall low NF hospitali-
zation rate. Higher C dose usage led to longer time to
collection.
There was no signiﬁcant difference in CD34 yield, neu-
tropenia, or NF hospitalization in patients >70 years. C+
G-CSF is an effective method of mobilization as proven by
optimal collection266
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Background: Mantle cell lymphoma (MCL) is a B-cell Non-
Hodgkin’s lymphoma (NHL) comprising 7% of adult NHL in
the US with an incidence of 4-8 cases per million persons
per year. Initial therapy of MCL includes a regimen with R-
CHOP or Hyper-CVAD. The best data for long term survival
includes cytarabine based therapy followed by autologous
hematopoietic stem cell transplantation (HSCT). In the re-
fractory/relapsed setting, allogeneic HSCT has been used
successfully. Barriers to allogeneic HSCT include lack of
donors and potential toxicities. Haploidentical donors
broaden the donor pool. To our knowledge, there is no
published data on outcomes with haploidentical HSCT in
MCL.
Methods: A retrospective chart review examining out-
comes in patients with MCL who underwent either autol-
ogous or allogeneic peripheral blood HSCT at Thomas
Jefferson University Hospital from January 2007 to January
2013.
Results: A total of 12 patients with MCL underwent HSCT
between 2007 to 2012. Nine of 12 patients were males.
Median age at transplant was 58 years (range 38 - 72). Me-
dian time from diagnosis to HSCT was 9.5 months. Five of 12
patients (4 haploidentical & 1 matched unrelated donor)
underwent allogeneic HSCT and 7of 12 patients underwent
autologous HSCT. In the allogeneic HSCT group, median
number of prior therapies was 2. One of 5 patients had re-
sidual disease prior to HSCT. Two of 5 patients had a mye-
loablative regimen; 3 had reduced intensity regimen. There
were no relapses or deaths in the allogeneic HSCT group.
Median progression free survival (PFS) as well as median
overall survival (OS) in this group was 35 months. Major
complications in allogeneic HSCT were acute skin GVHD
(3/5), CMV reactivation(1/5), HHV6 viremia(1/5), and acute
renal failure (1/5) requiring short term dialysis. In the
autologous HSCT group, the median number of prior thera-
pies was 1. Two of 7 patients had refractory disease prior to
autologous HSCT. Post autologous HSCT 2/7 patients relapsed
and 2/7 died. Major complications in this group were DVT
(2/7), enterocolitis (2/7), and CHF (1/7). Median PFS and OS
were 40 and 47 months respectively. Our patients who un-
derwent autologous HSCT were transplanted earlier (08/
2007 - 09/2010) than our patients who underwent allogeneicHSCT (01/2008 - 02/2012), leading to the difference in sur-
vival times.
Conclusions: Haploidentical HSCT offers a promising cura-
tive treatment for patients with MCL with expected and
manageable toxicities. Although a small number of patients,
this review of our data provides the background for further
study of the use of haploidentical HSCT in this group of
patients.
Autologous HSCT for patients with MCL can also provide
long term disease survival.
Further follow up of both groups will provide better data
regarding long term (>5 year) outcomes.
Therapy for MCL in the future is likely to include newer
agents (e.g. ibrutinib) in the front line, but HSCTwill remain a
viable option.267
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Background: The cytogenetic abnormality t(4;14)(p16;q32)
results in the fusion of immunoglobulin heavy chain
(IgH) gene on chromosome 14q32 with the ﬁbroblast
growth factor 3 (FGFR3) gene on chromosome 4p16 in
patients with multiple myeloma (MM), and is associated
with shorter progression-free survival (PFS) and overall
survival (OS). Recent studies indicate that treatment with
proteasome inhibitors (PI) may overcome the adverse
prognostic features. The aim of this study is to assess the
outcome of patients with t(4;14) after high-dose chemo-
therapy and autologous hematopoietic stem cell transplant
(Auto-HCT).
Methods: We identiﬁed 23 patients with MM who had
t(4;14) on conventional cytogenetic or ﬂuorescent in situ
hybridization (FISH) studies prior to auto-HCT at our insti-
tution between 2008 and 2013. We compared their out-
comes to a matched control group (n¼92) without t(4;14)
prior to HCT who were treated during the same time period.
Matching was based on age and response to the last therapy
prior to HCT.
Results: Patient characteristics are summarized in Table 1.
Median follow-up intervals were 41 months and 23
months in the t(4;14) and control groups, respectively. PFS
at 2 years was 18% (95% conﬁdence interval [CI], 6-37) in
the t(4;14) and 65% (95% CI, 53-75) in the control group
(Fig. 1), (p<.001; hazard ratio [HR], 5.2; 95% CI, 3.1-11.0). OS
at 2 years was 43% (95% CI, 22-62) in the t(4;14) and 81%
(95% CI, 70-89) in the control group (Fig. 2), (p<.001; HR,
5.2; 95% CI, 2.4-11.0). On multivariate analysis for PFS,
t(4;14) (p <.004; HR, 4.6; 95% CI, 2.5-8.4) emerged as the
only signiﬁcant adverse prognostic factor. Relapsed disease
at auto-HCT was associated with a trend for lower PFS
(p¼ .06; HR, 1.7; 95% CI, 0.97). On multivariate analysis for
OS, t(4;14) (p <.001; HR, 4.2; 95% CI, 1.9-9.2) and relapsed
Table 1
Patient Characteristics
Characteristic/Outcome t(4;14),
N¼23 (%)
Control,
N¼92 (%)
P
Median follow-up, months (range) 41 (18-46) 23 (1-76)
Median age, years (range) 59 (40-72) 59 (31-79)
60 12 (52) 48 (52)
>60 11(48) 44 (48) .99
Diagnosis to auto-HCT (%)
1 year 18 (78) 35 (38)
>1 year 5(22) 57 (62) .1
ISS stage (%)
I 3(13) 30 (33)
II 4(17) 19 (21)
III 12 (52) 15 (16)
Unknown 4(17) 28 (30) .04
Disease status (%)
Relapse 12 (52) 28 (30)
Other 11 (48) 64 (70) .05
Prior auto-HCT
Yes 0(0) 13 (14)
No 23(100) 79 (86) .05
Response prior to Auto-HCT (%)
CR/nCR/sCR 0(0) 18 (19)
VGPR 9 (39) 17 (18)
PR 10 (43) 41 (45)
SD 1(4) 10 (11)
PD 3(13) 6 (7) .6
Preparative regimen (%)
Melphalan alone 19 (83) 66 (72)
Melphalan + other 4(17) 25 (27) .3
.04
PI before auto-HCT 22 (91) 70 (76)
IMiD before auto-HCT 13 (57) 48 (52) .71
A capillary found in the lamina propria of esophagus from patient with TMA
(H&E 400x). There is ﬁbrin deposit (microthrombus) present in the space
between the basement membrane and separated endothelial cells ( * ) The
endothelial cells appear degenerated ( Y ) Fragmented red blood cells are in
the lumen.
MAC Myaloablative Conditioning: TBI 200cGy. Clofarabine 52 mg/m2
5days; AraC 1 gm/m2/d  6 days RTC: Reduced Toxicity Conditioning:
Bmulfan 4 mg/kg/d  4 days; Fludarabine 30 mg/m2/ d5 days; Alemtu-
zumab 2 mg/m21 days, 6 mg/m2 2 days
Figure 2. OS
Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205 S203disease at auto-HCT (p ¼.014; HR, 2.7; 95% CI, 1.2-6.2)
emerged as adverse prognostic factors.
Conclusion: Patients with t(4;14) have a signiﬁcantly shorter
PFS and OS even after an auto-SCT. Use of novel approaches
like post-transplant consolidation, maintenance, and im-
mune-based therapies should be explored in these high-risk
patients.Figure 1. PFS268
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